Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma
Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1). One...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2006, Vol.23 (2), p.295-300 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 300 |
|---|---|
| container_issue | 2 |
| container_start_page | 295 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 23 |
| creator | Avilés, Agustín Neri, Natividad Nambo, M Jesús Huerta-Guzman, Judith Cleto, Sergio |
| description | Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases).
Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed.
The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients. |
| doi_str_mv | 10.1385/MO:23:2:295 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_875561790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2393992611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-c05e0044ddfeae1c59ee4e39f16ca80e2d5bbf33a71c59cefebaf56575b1faa83</originalsourceid><addsrcrecordid>eNpVkE1Lw0AQhhdRbK2evMviVaL7kc1Hb1L8gpYerEdZJpvZpKVp4m4i5N-b0oJ6mmHeh3fgIeSas3suE_WwWE6FnIqpSNUJGXOp4oCpiJ3-2UfkwvsNY4IrkZ6TEY9iwVLJxuTzvXMFup7CLqemxKpuS3TQ9PQbne_8_xt42jqEtsJdS2tLy3VRBoWDHOnicb6iBfjWrQ3d9lVT1hVckjMLW49XxzkhH89Pq9lrMF--vM0e54GRPGwDwxQyFoZ5bhGQG5UihihTyyMDCUORqyyzUkK8zwxazMCqSMUq4xYgkRNye-htXP3VoW_1pu7cbnipk1ipiMcpG6C7A2Rc7b1Dqxu3rsD1mjO9N6kXSy2kFnowOdA3x8ouqzD_ZY_q5A8jVnBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>875561790</pqid></control><display><type>article</type><title>Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Avilés, Agustín ; Neri, Natividad ; Nambo, M Jesús ; Huerta-Guzman, Judith ; Cleto, Sergio</creator><creatorcontrib>Avilés, Agustín ; Neri, Natividad ; Nambo, M Jesús ; Huerta-Guzman, Judith ; Cleto, Sergio</creatorcontrib><description>Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases).
Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed.
The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1385/MO:23:2:295</identifier><identifier>PMID: 16720930</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject><![CDATA[Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Bleomycin - administration & dosage ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; Epirubicin - administration & dosage ; Female ; Humans ; Lymphoma, B-Cell, Marginal Zone - mortality ; Lymphoma, B-Cell, Marginal Zone - therapy ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - therapy ; Male ; Middle Aged ; Neoplasm Staging ; Oncology ; Prednisone - administration & dosage ; Remission Induction ; Stomach Neoplasms - mortality ; Stomach Neoplasms - therapy ; Vincristine - administration & dosage]]></subject><ispartof>Medical oncology (Northwood, London, England), 2006, Vol.23 (2), p.295-300</ispartof><rights>Humana Press Inc. 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c314t-c05e0044ddfeae1c59ee4e39f16ca80e2d5bbf33a71c59cefebaf56575b1faa83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16720930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Avilés, Agustín</creatorcontrib><creatorcontrib>Neri, Natividad</creatorcontrib><creatorcontrib>Nambo, M Jesús</creatorcontrib><creatorcontrib>Huerta-Guzman, Judith</creatorcontrib><creatorcontrib>Cleto, Sergio</creatorcontrib><title>Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><description>Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases).
Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed.
The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Bleomycin - administration & dosage</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphoma, B-Cell, Marginal Zone - mortality</subject><subject>Lymphoma, B-Cell, Marginal Zone - therapy</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prednisone - administration & dosage</subject><subject>Remission Induction</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - therapy</subject><subject>Vincristine - administration & dosage</subject><issn>1357-0560</issn><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVkE1Lw0AQhhdRbK2evMviVaL7kc1Hb1L8gpYerEdZJpvZpKVp4m4i5N-b0oJ6mmHeh3fgIeSas3suE_WwWE6FnIqpSNUJGXOp4oCpiJ3-2UfkwvsNY4IrkZ6TEY9iwVLJxuTzvXMFup7CLqemxKpuS3TQ9PQbne_8_xt42jqEtsJdS2tLy3VRBoWDHOnicb6iBfjWrQ3d9lVT1hVckjMLW49XxzkhH89Pq9lrMF--vM0e54GRPGwDwxQyFoZ5bhGQG5UihihTyyMDCUORqyyzUkK8zwxazMCqSMUq4xYgkRNye-htXP3VoW_1pu7cbnipk1ipiMcpG6C7A2Rc7b1Dqxu3rsD1mjO9N6kXSy2kFnowOdA3x8ouqzD_ZY_q5A8jVnBg</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Avilés, Agustín</creator><creator>Neri, Natividad</creator><creator>Nambo, M Jesús</creator><creator>Huerta-Guzman, Judith</creator><creator>Cleto, Sergio</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>2006</creationdate><title>Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma</title><author>Avilés, Agustín ; Neri, Natividad ; Nambo, M Jesús ; Huerta-Guzman, Judith ; Cleto, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-c05e0044ddfeae1c59ee4e39f16ca80e2d5bbf33a71c59cefebaf56575b1faa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Bleomycin - administration & dosage</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphoma, B-Cell, Marginal Zone - mortality</topic><topic>Lymphoma, B-Cell, Marginal Zone - therapy</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prednisone - administration & dosage</topic><topic>Remission Induction</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - therapy</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avilés, Agustín</creatorcontrib><creatorcontrib>Neri, Natividad</creatorcontrib><creatorcontrib>Nambo, M Jesús</creatorcontrib><creatorcontrib>Huerta-Guzman, Judith</creatorcontrib><creatorcontrib>Cleto, Sergio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avilés, Agustín</au><au>Neri, Natividad</au><au>Nambo, M Jesús</au><au>Huerta-Guzman, Judith</au><au>Cleto, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><addtitle>Med Oncol</addtitle><date>2006</date><risdate>2006</risdate><volume>23</volume><issue>2</issue><spage>295</spage><epage>300</epage><pages>295-300</pages><issn>1357-0560</issn><eissn>1357-0560</eissn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1).
One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases).
Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed.
The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>16720930</pmid><doi>10.1385/MO:23:2:295</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2006, Vol.23 (2), p.295-300 |
| issn | 1357-0560 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_875561790 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bleomycin - administration & dosage Cyclophosphamide - administration & dosage Disease-Free Survival Epirubicin - administration & dosage Female Humans Lymphoma, B-Cell, Marginal Zone - mortality Lymphoma, B-Cell, Marginal Zone - therapy Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - therapy Male Middle Aged Neoplasm Staging Oncology Prednisone - administration & dosage Remission Induction Stomach Neoplasms - mortality Stomach Neoplasms - therapy Vincristine - administration & dosage |
| title | Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T08%3A50%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgery%20and%20chemotherapy%20versus%20chemotherapy%20as%20treatment%20of%20high-grade%20MALT%20gastric%20lymphoma&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Avil%C3%A9s,%20Agust%C3%ADn&rft.date=2006&rft.volume=23&rft.issue=2&rft.spage=295&rft.epage=300&rft.pages=295-300&rft.issn=1357-0560&rft.eissn=1357-0560&rft.coden=MONCEZ&rft_id=info:doi/10.1385/MO:23:2:295&rft_dat=%3Cproquest_cross%3E2393992611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=875561790&rft_id=info:pmid/16720930&rfr_iscdi=true |